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Tuberculosis clinical presentation and
treatment outcomes in pregnancy: a
prospective cohort study
Brittney J. van de Water1* , Meredith B. Brooks1, Chuan-Chin Huang1, Letizia Trevisi1, Leonid Lecca1,2,
Carmen Contreras2, Jerome Galea2,3, Roger Calderon2, Rosa Yataco2, Megan Murray1,2 and Mercedes C. Becerra1,2

Abstract
Background: There is limited research to guide TB treatment specifically in pregnant women and few studies have
described the presentation of TB in pregnant women. We aimed to understand TB presentation and treatment
outcomes in pregnant women in a low HIV burden setting. We describe a cohort of women of childbearing age
treated for TB disease in Lima, Peru, and compare clinical presentation and treatment outcomes among pregnant
and non-pregnant women between 2009 and 2012, including 36 pregnant women.
Methods: This is a prospective cohort study. Subjects were recruited from across 106 public health centers in Lima,
Peru. Baseline demographic, medical history, and drug-susceptibility test results were collected. We used descriptive
statistics to describe demographic and clinical characteristics of the women using Pearson chi-squared, Fisher’s
exact tests, or Kruskal-Wallis.
Results: Among 4500 individuals with pulmonary TB disease, 1334 women were included in analysis with 36
(2.69%) pregnant women. Pregnant women had similar demographics, past medical histories, and clinical
presentation to non-pregnant women, except being more likely to be married (p = 0.01) and have cardiac disease
(p = 0.04) and less likely to have weight loss (p = 0.05). Twenty (71.4%) pregnant women had pan-susceptible TB
compared with 616 (63.1%) non-pregnant women; four (14.3%) pregnant women had mono-resistant TB compared
with 154 (15.8%) non-pregnant women; and four (14.3%) pregnant women had multi-drug-resistant TB compared
with 140 (14.3%) of non-pregnant women (p = 0.53). Twenty-eight (96.6%) pregnant women had a successful
outcome (cure, completed treatment, treatment ended early by clinical team) while one (3.4%) had an unsuccessful
outcome (treatment failed) and 1074 (97.3%) non-pregnant women had a successful outcome while 30 (2.7%) had
an unsuccessful outcome (p = 0.56).
Conclusion: In this cohort with low HIV co-infection, we found high TB treatment success rates in both pregnant
and non-pregnant women, irrespective of drug-susceptibility profiles. If treated appropriately, pregnant women
with TB disease can have successful outcomes.
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Background
Globally each year, 3.2 million women become sick with
tuberculosis (TB) [1]. In low- and middle-income countries, HIV/AIDS, maternal conditions, and TB account for
nearly 50% of deaths among women in their reproductive
years [1]. Additionally, with improvements in obstetrical
care, non-obstetric causes including infectious diseases account for nearly 28% of maternal mortality worldwide [2].
Approximately 216,500 pregnant women were estimated
to have TB in 2011, and it is not known how many pregnant women had drug-resistant TB (DR-TB) [3].
Diagnosing TB disease in pregnant women is challenging
because some non-specific symptoms are common to both
TB and pregnancy, such as shortness of breath and fatigue
[4, 5]. However, when TB disease is diagnosed and treated,
successful treatment outcomes have been seen in small cohorts of pregnant women [6]. Failure to treat TB during
pregnancy increases risk of preventable death in both the
woman and her child, thus TB treatment is recommended
unless the risks outweigh the benefit of treatment [7].
Currently, first-line treatment for drug-susceptible TB is recommended during pregnancy [1]. First-line TB regimens—
with isoniazid, rifampicin, pyrazinamide, and ethambutol—
have been shown to be safe for pregnant women throughout
all trimesters [8, 9]. Second-line drugs are also used during
pregnancy, with more limited safety evidence [6, 10]. For example, aminoglycosides (such as kanamycin, amikacin, and
streptomycin) should be avoided, especially within the first 20
weeks of pregnancy, due to the risk for ototoxicity and fetal
malformation. Ethionamide and prothionamide can increase
the risk of nausea and vomiting during pregnancy, thus these
drugs are often avoided until after delivery [10]. However,
most other second-line drugs are considered U.S. Food and
Drug Administration class B (animal studies demonstrate no
risk, no human studies) or C (animal studies demonstrate risk,
no human studies), meaning they can be used in pregnancy
without known adverse effects [10].
To our knowledge, pregnant women’s treatment outcomes
have not been compared to non-pregnant women of the
same age. We aimed to understand TB presentation and
treatment outcomes in pregnant women in a low HIV burden setting. Thus, we describe a cohort of women of childbearing age treated for TB disease in Lima, Peru, and
compared clinical presentation and treatment outcomes
among pregnant and non-pregnant women. Additionally, we
describe outcomes among women with DR-TB, because literature is scant among this sub-population. We hypothesized
that pregnant and non-pregnant women will have similar
presentations and treatment outcomes for TB disease.
Methods
Study setting

This is a sub-study of a prospective cohort study of
household TB transmission conducted in Lima, Peru,
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described in detail elsewhere [11]. In brief, over a threeyear period subjects were recruited in 106 public health
centers across the study catchment area of approximately 3.3 million people. Between September 1, 2009
and August 29, 2012, individuals age 16 years and older
who were diagnosed with pulmonary TB disease were
invited to participate in the study (i.e., index subjects,
N = 4500). After visiting recruited patients’ homes, consenting household contacts were enrolled as well. Study
staff conducted interviews with index subjects to record
baseline characteristics and also conducted follow-up interviews at two, six, 12, and 24 months. For patients with
DR-TB, follow-up interviewers were also conducted at
36 and 48 months [11].
Study design and study population

This is a descriptive secondary analysis of data from the
cohort enrolled in the above parent study. Here we
analyze the sub-set of women of childbearing age, which
we defined as < 45 years. Sixteen years was the minimum
age because only individuals > 15 years were enrolled as
index subjects in the parent study [11].
Sources of data and study measures

Baseline demographics and medical history were collected
through an interview with a study staff member, and drugsusceptibility testing (DST) results for first- and second-line
TB drugs were obtained through sputum collection and laboratory testing. Individuals were evaluated for TB disease
with sputum smear microscopy with Ziehl-Neelsen staining
and culture on solid Lowenstein-Jensen medium. In the absence of bacteriological confirmation of TB disease, a clinical
diagnosis was based on evaluation by a medical doctor and
radiography. Sputa were initially tested for drug sensitivity by
using Lowenstein-Jensen medium while second-line DST
was performed on Middlebrook 7H11 agar. Pregnancy was
self-reported and confirmed with a urine test. Individuals
with missing information on pregnancy status were excluded
from analysis.
Outcomes were classified by local clinicians and extracted
from the medical record. Outcomes were then linked to
match 2013 WHO guidelines [12] for standardization of
reporting, where possible. Composite outcomes are used;
outcomes were categorized as either successful or unsuccessful (Table 1). We also report outcomes from individuals who
were still on active treatment at the end of the study period,
were lost to follow-up, or who were not evaluated for an outcome, but exclude them from the larger analysis. Subjects
who were lost to follow up were excluded because it was impossible to determine whether they successfully completed
treatment at another health facility outside of our catchment
area or whether they experienced worsening of disease and,
consequently, had an unsuccessful treatment outcome.
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Table 1 Outcome variable definitions
Outcome

Composite
Outcome

Definition (DS- definition / DR- definition)

Source

Cured

Successful

A pulmonary TB patient with bacteriologically confirmed TB at the beginning of
treatment who was smear- or culture-negative in the last month of treatment and on at
least one previous occasion. / Treatment completed as recommended by the national
policy without evidence of failure AND three or more consecutive cultures taken at least
30 days apart are negative after the intensive phase.

WHO [12] Both

Treatment
Completed

Successful

A TB patient who completed treatment without evidence of failure BUT with no record
to show that sputum smear or culture results in the last month of treatment and on at
least one previous occasion were negative, either because tests were not done or
because results are unavailable. / Treatment completed as recommended by the national
policy without evidence of failure BUT no record that three or more consecutive cultures
taken at least 30 days apart are negative after the intensive phase.

WHO [12] Both

Treatment
Successful
completed early

If the patient received more than 5 months of treatment (but less than 6 months) AND
the outcome recorded by the treating physician was “completed dose” or “cured.”

Local
DSphysicians

Died

A TB patient who dies for any reason before starting treatment or during the course of
treatment.

WHO [12] Both

Treatment failed Unsuccessful

A TB patient whose sputum smear or culture is positive at month 5 or later during
treatment. / Treatment terminated or need for permanent regimen change of at least
two anti-TB drugs because of: lack of conversion by the end of the intensive phase; bacteriological reversion in the continuation phase after conversion to negative; evidence of
additional acquired resistance to fluoroquinolones; adverse drug reactions.

WHO [12] Both

Clinical default

Unsuccessful

If the patient did not receive at least 18 months of treatment AND the outcome recorded Local
DRby the treating physician was “cure.”
physicians

Lost to follow
up

Lost to follow
up

A TB patient who did not start treatment or whose treatment was interrupted for 2
consecutive months or more.

Not evaluated

Still on active
treatment

Unsuccessful

DS-, DR-,
or Both

WHO12

Both

Not evaluated A TB patient for whom no treatment outcome is assigned. This includes patients
“transferred out” to another treatment unit as well as patients for whom the treatment
outcome is unknown to the reporting unit.

WHO12

Both

Still on active
treatment

Local
Both
physicians

If no outcome was provided because the patient was still on active treatment.

Cavity on chest x-ray was defined by radiologist reading. Isolates were classified as drug-susceptible if the
drug-susceptibility test (DST) was susceptible to all
drugs tested (including cycloserine, ethambutol, ethionamide, levofloxacin, pyrazinamide, isoniazid, rifampin,
and streptomycin), while drug-resistant TB was defined
as mono-, poly-, or multi-drug resistant. Age was selfreported. Marital status (married, divorced/separated,
single, widowed), student status (student, not a student),
education history (less than high school, high school or
greater), medical history (cardiac disease, high blood
pressure, asthma, kidney disease, diabetes, and history of
TB) and clinical symptoms (cough, cough with blood,
cough with phlegm, fever, weight loss, difficult breathing, and night sweats) were all self-reported. HIV status
was confirmed with an ELISA blood test and Western
Blot or indirect immunofluorescence assay [13]. Treatment delay was defined as the median number of days
from symptom onset to TB diagnosis.
Analysis

Categorical variables were reported as frequency and percent, and continuous variables were reported as median
and interquartile range. To compare sociodemographic

data, clinical symptoms, and TB treatment outcomes between pregnant and non-pregnant women, we used Pearson chi-squared, or Fisher’s exact tests for small cell sizes
(fewer than five per cell). The Kruskal Wallis test was used
to compare medians of the variable “age.” All analyses
used SAS 9.4 (Cary, NC).
Ethics review

All study participants provided voluntary, written informed
consent prior to study participation. The Harvard School of
Public Health (reference number 19332) and Peru’s Research
Ethics Committee of the National Institute of Health provided Institutional Review Board approval.

Results
A total of 4500 individuals with pulmonary TB were enrolled in the study of whom 1368 were women between
the ages of 16 and 45 years. Thirty-four women were excluded from analysis because their pregnancy status was
unknown. Among the 1334 participants who met inclusion criteria (Fig. 1), 36 (2.7%) were pregnant; these had
a median age of 24.5 (IQR 21–30.5) while 1298 (97.3%)
non-pregnant women had a median age of 25 (IQR 20–
32) (p = 0.9435) (Table 1). Most pregnant women were
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Fig. 1 Participant flow diagram for inclusion in analysis

married (66.7%), were not students (94.4%), had less
than a high school education (66.7%), were HIV-negative
(97.1%), and on average, had low rates of comorbidities.
Most demographics, past medical history, and symptoms
among pregnant and non-pregnant women were not statistically different. However, pregnant women were more
likely to be married (p = 0.01), have cardiac disease (p =
0.04), and have less weight loss (p = 0.05).
Drug-susceptibility testing (DST) data were available
for 1004 (75.26%) women. Eight (22.2%) pregnant
women had a clinical diagnosis of TB, similarly, 322
(24.8%) non-pregnant women had a clinical diagnosis of
TB (p = 0.72). All other women had bacteriologically
confirmed pulmonary TB. Twenty (71.4%) pregnant
women had pan-susceptible TB compared with 616
(63.1%) non-pregnant women; four (14.3%) pregnant
women had mono-resistant TB compared with 154
(15.8%) non-pregnant women, and four (14.3%) pregnant
women had MDR-TB compared with 140 (14.3%) nonpregnant women (p = 0.53). Among the eight pregnant
women with drug-resistant TB, two completed treatment, five were cured, and one was lost to follow up.
Details of TB presentation, resistance profiles, and treatment regimens are reported in Table 2.
Among all women, 1319 (98.8%) had a treatment outcome
reported (Table 3). Among pregnant women, 28 (96.6%) had
a successful outcome (cure, completed treatment, treatment
ended early by clinical team) while one (3.5%) had an unsuccessful outcome (treatment failed 5 months or later)
(Table 4). One-thousand and seventy-four (98.4%) nonpregnant women had a successful outcome while 17 (1.6%)
had an unsuccessful outcome (p = 0.38).

Discussion
We observed similar clinical presentations and similar
TB treatment outcomes between pregnant and nonpregnant women of childbearing age, regardless of the
drug-resistance profile of the infecting strain. Pregnant
women were more frequently married and, as expected,
had less weight loss than non-pregnant women. Few

other studies have reported on TB treatment outcomes
among pregnant women, including DR-TB. One review
found only nine published case reports describing DRTB treatment during pregnancy; taken together those
studies reported outcomes for a total of 73 women [6].
To our knowledge, no other studies have compared
presentation or TB treatment outcomes among pregnant
and non-pregnant women of childbearing age. Nor have
other studies described presentation or symptomology of
pregnant women with TB.
We found that pregnant women, regardless of drug resistance, can have successful treatment outcomes similar
to non-pregnant women of childbearing age. Some studies
have reported poor outcomes among pregnant women
with TB [14, 15]; however, those focused on poor obstetric
and infant outcomes, mostly in HIV co-infected women,
and did not highlight TB treatment outcomes specifically.
Another study, also in a largely HIV co-infected cohort,
did highlight TB treatment outcomes, where 45% of the
73 women had unfavorable TB outcomes [16].
A recent systematic review of TB in pregnancy included 35 studies describing diagnosis, treatment, and
follow-up [17]. Fourteen of these studies included pregnant women on TB treatment; 332/375 (88%) of women
were cured. Four papers were specific to drug-resistant
TB and pregnancy, reporting outcomes among a total of
55 women (one study including 38 women) with 42 being successfully treated (76%) [18–21]. Delay in treatment or loss to follow up were found to be the main
causes of mortality and morbidity among mothers and
infants. With appropriate treatment and close follow-up,
pregnant women sick with TB can be cured and have
positive maternal outcomes. Integration of TB screening
programs with maternal care services could be an efficient way to detect cases in women that might otherwise
remain undetected, as most TB in pregnancy is diagnosed in the third trimester of pregnancy or in the postpartum period [3, 4, 22, 23]. Another 2017 systematic review and meta-analysis including 13 studies found that
TB disease in pregnancy is associated with adverse
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Table 2 Baseline characteristics of pregnant and non-pregnant women diagnosed with pulmonary tuberculosis
Characteristic

N

Pregnant

Non-pregnant

p-value

Age (Median (IQR))

1334

24.5 (21–30.5)

25 (20–32)

0.94a

Marital status

1325

0.01

Married

24 (66.7)

504 (39.1)

Divorced/separated

0 (0.0)

47 (3.7)

Single

11 (30.6)

734 (56.9)

Widowed

1 (2.8)

4 (0.3)

2 (5.6)

200 (15.5)

Student

1325

Education

1332

0.10
0.67

Less than HS

24 (66.7)

819 (63.2)

HS or greater

12 (33.3)

477 (36.8)

HIV positive

1321

1 (2.9)

28 (2.1)

0.54b

Cardiac disease

1330

3 (8.3)

27 (2.1)

0.04b

High blood pressure

1326

2 (5.7)

45 (3.5)

0.35b

Asthma

1330

4 (11.4)

120 (9.3)

0.56b

Kidney disease

1328

1 (2.9)

46 (3.6)

1.00b

Diabetes

1318

0 (0.0)

14 (1.1)

1.00b

History of TB

1331

6 (16.7)

155 (12.0)

0.43b

Microbiologically confirmed TB

1334

34 (94.4)

1179 (90.8)

0.77b

Treatment delay

1320

22 (14.0–48.5)

24 (13.0–41.5)

0.53a

Cavity on CXR

1304

5 (15.6)

348 (27.4)

0.14

Cough

1334

34 (94.4)

1102 (84.9)

0.11

Cough with blood

1332

12 (33.3)

318 (24.5)

0.23

Cough with phlegm

1332

32 (88.9)

978 (75.5)

0.06

Fever

1332

8 (22.2)

379 (29.2)

0.36

Lost weight

1316

22 (61.1)

966 (75.5)

0.05

Difficulty breathing

1332

24 (66.7)

707 (54.6)

0.15

Night sweats

1330

20 (55.6)

658 (50.9)

0.58

Resistance pattern

1004
20 (71.4)

616 (63.1)

Symptoms

Pan-susceptible
Mono-resistant

4 (14.3)

154 (15.8)

Poly-resistant

0 (0.0)

66 (6.8)

4 (14.3)

140 (14.3)

Multi-drug resistant +/−
a

0.53

Kruskal-Wallis;

b

Fisher’s Exact

maternal and perinatal outcomes [7]. Our study adds
that high rates of cure can be achieved in pregnant
women treated for TB.
In addition to TB, HIV co-infection is also known to
complicate pregnancy outcomes [6]. In this Lima cohort,
only one pregnant woman was HIV co-infected [13].
However, much of the research on TB and pregnancy
focuses on women with HIV or has been completed in
settings with a high prevalence of HIV [5, 10, 14, 16, 18].
Many of the observed poor maternal and perinatal outcomes in those studies are due to HIV co-infection and

not only to TB. Thus, our report adds to literature supporting good TB treatment outcomes among pregnant
women without HIV co-infection.
There is a pressing need to expand evidence to
optimize the delivery of DS- and DR-TB treatment for
pregnant women [24]. Maternal health services could
provide an important entry point to the healthcare system when women can be screened and treated for TB
[24, 25]. If not diagnosed or treated early, there is a high
risk of poor maternal and perinatal outcomes. Studies
have reported a two-fold increase in premature birth
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Table 3 Characteristics and outcomes of pregnant women with confirmed drug-resistant tuberculosis (n=8)
Participant Age TB Presentation

Baseline DST profile

TB treatment
regimen

Treatment
Outcome

1

19

• Smear +++ pulmonary TB
• No history of TB
• Cavity seen on CXR
• Cough, cough with blood, cough with phlegm, weight loss,
difficulty breathing

MDR (Resistant: INH, RIF,
SM)

CS
EMB ETH LEVO
PZA

Treatment
completed

2

21

• Smear + pulmonary TB
• History of TB
• Cough, cough with phlegm, difficulty breathing, night sweats

MDR
(Resistant: INH, RIF, SM)

CS
EMB ETH LEVO
PZA

Lost to follow
up

3

29

• Smear – pulmonary TB
• No history of TB
• Cough, cough with blood, cough with phlegm, difficulty
breathing, night sweats

Mono-resistant (Resistant
SM)

EMB
INH PZA
RIF

Cured

4

30

• Smear – pulmonary TB
• No history of TB
• Cough, cough with blood, cough with phlegm, weight loss,
difficulty breathing, night sweats

Mono-resistant (Resistant:
EMB)

EMB INH PZA
RIF

Cured

5

34

• Smear ++ pulmonary TB
• History of TB
• Cough, cough with phlegm, weight loss

MDR (Resistant: PZA, INH,
EMB, RIF, SM)

CS LEVO PAS
PZA

Cured

6

17

• Smear ++ pulmonary TB
• No history of TB
• History of asthma
• Difficulty breathing, night sweats

Mono-resistant (Resistant:
SM)

EMB INH LEVO
PZA

Cured

7

33

• Smear + pulmonary TB
• History of TB
• Cough, cough with phlegm, weight loss

Mono-resistant (Resistant:
RIF)a

EMB INH PZA
RIF

Cured

8

25

• Smear +++ pulmonary TB
• No history of TB
• Cough, cough with blood, cough with phlegm, weight loss

MDR (Resistant: INH, EMB,
RIF, SM)

EMB INH PZA
RIF

Treatment
completed

Abbreviations: CXR chest x-ray, CS cycloserine, EMB ethambutol, ETH ethionamide, LEVO levofloxacin, PZA pyrazinamide, INH isoniazid, RIF rifampin,
SM streptomycin
a
RIF resistance was detected on a second drug susceptible test

Table 4 Successful versus non-successful outcomes among pregnant and non-pregnant women with pulmonary tuberculosis
Successful outcome
Cured

Non-pregnant women n=1285

p-value

28 (96.6)

1072 (97.3)

0.56a

15 (44.1)

643 (50.1)

0.35

Treatment completed

12 (35.3)

400 (31.2)

0.75

Treatment ended early by clinical team

1 (2.9)

29 (2.3)

0.56a

Non-successful outcome

1 (2.9)

30 (2.7)

Died

0 (0.0)

13 (1.0)

1.00a

Treatment failed

1 (2.9)

15 (1.2)

0.34a

Clinical default (DR-)

0 (0.0

2 (0.2)

1.00a

Censored

a

Pregnant women n=34

5 (14.7)

183 (14.2)

On active treatment

1 (2.9)

54 (4.2)

1.00a

Lost to follow up

4 (11.8)

97 (7.6)

1.00a

Not evaluated

0 (0.0)

30 (2.3)

1.00a

Fisher’s Exact test
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and a six-fold increase in perinatal deaths in pregnant
women who have delayed or interrupted TB treatment
[7, 26]. WHO guidelines recommend using standardized
regimens during pregnancy (including 2 months isoniazid,
rifampicin, pyrazinamide, and ethambutol, followed by
4 months of isoniazid and rifampicin), and one study has
shown these drugs to be non-teratogenic [9, 27]. Although
evidence is limited, there is growing observational evidence that some DR-TB medications are safe during pregnancy [19, 20, 28]. Pregnant women should have prompt
access to advances in TB treatment; however, due to the
frequent exclusion of pregnant women from TB research
studies, they are often a neglected population [24].
Notably, there is a dual benefit to treating a pregnant
woman sick with TB: both to cure her and to eliminate
the risk of her infecting her infant. The risk of transmission of TB can be high in the first 3 weeks of life; in the
high HIV burden setting of Durban, South Africa, one
study found that 15% of mothers transmitted TB to their
infants [15]. Treating pregnant women directly protects
infants, who face an exceedingly high risk of progression
from TB infection to disease in the first year of life [29].
Our study had several limitations. First, the number of
pregnant women in this cohort was relatively small, potentially making generalizability difficult. Second, few
women in this cohort were HIV infected, thus making
findings difficult to generalize in higher HIV burden settings. Additionally, we excluded some women from the
primary analysis (successful/non-successful) if their TB
treatment outcome was on active treatment, not evaluated, or lost to follow up. Had we included all of these
outcomes as non-successful, we may have biased our results negatively. In addition, other studies have shown that
most TB in pregnant women is diagnosed in the third trimester [22, 30]. We did not assess the trimester of pregnancy in this cohort of women. Finally, pregnancy and
neonatal outcomes were not collected, thus we were unable to assess the health of the women and infants after
TB treatment. Despite these limitations, this report provides evidence that pregnant women have a similar clinical
presentation as do non-pregnant women and underscores
that successful treatment outcomes among pregnant
women with TB disease should be expected, regardless of
the infecting strain’s drug-susceptibility profile.

Conclusions
In sum, we found that pregnant women had similar rates
of DS-TB and DR-TB as non-pregnant women, similar
presentation, and similar treatment outcomes. Pregnant
women can have successful treatment outcomes, regardless of the infecting strain. Further work is needed to
understand how to leverage maternal care services to
promote TB prevention, diagnosis, and treatment among
pregnant women.
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